Unless the appointing director limits the time or scope of the appointment, the appointment is effective for all purposes until the earlier of (i) the appointing director ceasing to be a director; (ii) the appointing director terminating the appointment; or (iii) the occurrence, with respect to the alternate, of any of the circumstances under which a director shall vacate his or her office. The appointment of an alternate director does not in itself diminish the responsibility of the appointing director as a director. An alternate director is solely responsible for his or her actions and omissions and is not deemed an agent of the appointing director. Under the Companies Law, external directors cannot generally appoint alternate directors, and a person who is not qualified to be appointed as an “independent” director may not be appointed as an alternate to an independent director. See “Item 6—Directors, Senior Management and Employees—C. Board Practices.” At present, there are no effective appointments of alternate directors for our Board.

Biomoda, Inc. (OTCBB:BMOD) is a cancer diagnostics company focused on the development of accurate, inexpensive and noninvasive tests for the early detection of cancer in large populations. In addition to its first product for lung cancer, diagnostic assays for cervical, breast, colorectal, bladder, and oral cancers are targeted for development.

Kaivosoja, E. et al. Chemical and physical properties of regenerative medicine materials controlling stem cell fate. Ann. Med. 44, 635–650 (2012).

        We are a clinical-stage biopharmaceutical company using our proprietary peptide chemistry platform to develop novel therapeutics for the treatment of serious diseases that are caused by excessive or uncontrolled activation of the complement system, a critical component of the immune system. Inappropriate activation of the complement system can quickly turn it from a beneficial defense system to an aggressor that plays a major role in immune and inflammatory diseases. The complement system, which consists of approximately 30 interacting proteins, offers a target-rich opportunity for us to leverage our proprietary peptide chemistry platform, which was pioneered by Nobel Laureate Dr. Jack Szostak and allows us to inhibit certain uncontrolled complement pathway factors involved in complement-mediated diseases. Known as our Extreme Diversity platform, this proprietary macrocyclic peptide chemistry technology allows us to produce synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. We believe this technology will allow us to pursue challenging targets for which only monoclonal antibodies have been developed.

In this study, using rat ascending aortic stenosis (AAS) model and proteomic and biochemical analyses, we investigated the holistic mechanisms underlying the therapeutic effect of QSYQ on CH. By comparing the efficacies and mechanisms of QSYQ, its single ingredient ASIV, DLA, R1, DO and various ingredient combinations we showed the rationality of QSYQ formula design, supporting that a regime containing multiple components is more effective than individual treatment for complex diseases16.

        Costs for assets not yet placed into service is capitalized as construction in progress. Maintenance and repair costs are expensed as incurred.

Acorda Therapeutics, Inc. (NasdaqGM:ACOR ) Acorda Therapeutics is a biotechnology company developing therapies for spinal cord injury, multiple sclerosis and related nervous system disorders. The Company’s marketed products include Zanaflex Capsules® (tizanidine hydrochloride), a short-acting drug for the management of spasticity. The Company’s pipeline includes a number of products in development for the treatment, regeneration and repair of the spinal cord and brain.

The Anti- Kickback Statute makes it illegal for any person, including a prescription drug manufacturer (or a party acting on its behalf) to knowingly and willfully solicit, receive, offer, or pay any remuneration that is intended to induce the referral of business, including the purchase, order, or prescription of a particular drug, for which payment may be made under a federal healthcare program, such as Medicare or Medicaid.

        We expect our expenses to increase in connection with our ongoing development activities, particularly as we advance the Phase 3 clinical program for zilucoplan, continue clinical trials of zilucoplan in additional indications advance the development of our pipeline programs, initiate new

In addition, as a “foreign private issuer,” we are exempt from the rules and regulations under the Exchange Act related to the furnishing and content of proxy statements and certain individual executive compensation information, and our officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. Furthermore, foreign private issuers are not required to file their annual report on Form 20-F until 120 days after the end of each fiscal year, while U.S. domestic issuers that are accelerated filers are required to file their annual report on Form 10-K within 75 days after the end of each fiscal year and U.S. domestic issuers that are large accelerated filers are required to file their annual report on Form 10-K within 60 days after the end of each fiscal year. Additionally, as a “foreign private issuer,” we are also not subject to the requirements of Regulation FD (Fair Disclosure) promulgated under the Exchange Act. These exemptions and leniencies reduce the frequency and scope of information and protections to which you are entitled as an investor.

Increased cGMP in platelets through action of NO released into the blood vessel lumen can decrease platelet activation and adhesion to the surface of endothelium37. NO can also regulate the cellular environment within the vessel wall by inhibiting the activity of growth factors released from cells within the vessel wall and from platelets on the endothelial surface38. Both water and hydroalcoholic extracts of boswellia serrata’s gum resin enhance PT and APTT coagulation time periods39. Extracts of boswellia serrata’s gum resin can be considered as an effective antiatherogenic resource for preventing coronary artery diseases and may serve as ideal source to isolate lead compounds of antiplatelet and anticoagulant therapeutics39. All the evidences raise the necessity to investigate the effects of β-BA on blood coagulation. As is manifested by the results, β-BA can significantly prolong TT, PT and APTT, and decrease FIB (Table 1). PT is referred to evaluate the overall efficiency of extrinsic clotting pathway, and prolonged PT indicates a deficiency in coagulation factors V, VII and X. On the other hand, APTT indicates the intrinsic clotting activity, and prolonged APTT usually represents a deficiency in factors VIII, IX, XI, XII and Von Willebrand’s factor40. According to the results, β-BA improves blood coagulation through extrinsic and intrinsic pathways. Additionally, it has been reported that β-BA induces release of arachidonic acids from platelets41, which in turn can induces endothelin-1 (ET-1) expression in endothelial cells42, Which has been identified as a key player of endothelial dysfunction. Pretreatment of β-BA results in a significant decrease of blood ET-1 level compared to model group (see Supplementary Fig. S3 online), which provides a better insight of β-BA’s protective mechanism.

        As of December 31, 2018, our executive officers and directors, combined with our stockholders who owned more than 5% of our outstanding common stock and their affiliates in the aggregate, beneficially own shares representing approximately 46.9% of our common stock. As a result, if these stockholders were to choose to act together, they would be able to control all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, would control the election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. This concentration of ownership control may: